Analyst consensus rating
Trevi Therapeutics Analyst Rating: Strong Buy
Direct answer
Trevi Therapeutics's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $28.18.
Forecast evidence checked November 3, 2026.
Get free Trevi Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $13.63
- Average price target
- $28.18
- High price target
- $40.00
- Low price target
- $23.00
- Low target gap
- +68.7%
- Target upside
- +106.8%
- High target gap
- +193.5%
- Target range width
- 124.7%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- November 3, 2026
- Valid through
- November 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Trevi Therapeutics?
Trevi Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $28.18.
How far are Trevi Therapeutics's low and high targets from the recorded price?
The low target implies +68.7%, while the high target implies +193.5%.
How many analysts are included in Trevi Therapeutics's consensus?
The verified consensus includes 11 analysts.
How is Trevi Therapeutics's target upside or downside calculated?
The average target of $28.18 is divided by the recorded price of $13.63, then one is subtracted to produce +106.8%. This does not guarantee a future return.
When was Trevi Therapeutics's analyst forecast verified?
The data was verified on 2026-11-03. The dataset is valid through 2026-11-10.